Skip to content

Cue Biopharma, Inc.

CUE· NasdaqCore metricsCIK 1645460

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -5.61%
Market cap
$137.01M
7.75M shares
Filings
558
$132.00K
Q3 2026+195.7% FY25 yoy
-$50.02M
Q3 2026N/M FY25 yoy
-$47.10M
Q3 2026N/M FY25 yoy
-$50.15M
Q3 2026derivedN/M FY25 yoy
-$4.74
Q3 2026N/M FY25 yoy
$57.94M
Q3 2026+20.8% FY25 yoy
$137.01M
—
3.8×
3.6×
-37.39%
—

Twelve months to Sep 30, 2026 · derived

Price

$17.67+2,535.35%+$17.00past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$27.47MFY 2025
$27.47M0FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$27,466,000reported
FY 20242024-12-31$9,287,000reported
FY 20232023-12-31$5,490,000reported
FY 20222022-12-31$1,245,000reported
FY 20212021-12-31$14,941,370reported
FY 20202020-12-31$3,154,325reported
FY 20192019-12-31$3,458,331reported
FY 20182018-12-31$1,142,604reported

Capital returns

Dividends and buybacks · FY2019 to FY2023
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2023—$0.00$0.00—48.64M sh+12.7%—
FY2022—$200.00K$200.00K—43.17M sh+30.8%—
FY2021—$750.13K$750.13K—33.01M sh+8.4%—
FY2020—$271.05K$271.05K—30.46M sh+14.6%—
FY2019—$91.03K$91.03K—26.58M sh+28.2%—

Pharmaceutical preparations

Cue Biopharma, Inc. is the 147th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Cue Biopharma, Inc. · CIK 1645460 · Engraved from SEC EDGAR